Ralliant (NYSE:RAL) Director Kate Mitchell Buys 2,350 Shares of Stock

Ralliant Corporation (NYSE:RAL) Director Kate Mitchell purchased 2,350 shares of Ralliant stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $42.48 per share, with a total value of $99,828.00. Following the acquisition, the director directly owned 8,411 shares in the company, valued at $357,299.28. This trade represents a 38.77% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ralliant Price Performance

Ralliant stock opened at $42.68 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $4.81 billion and a P/E ratio of 21.78. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $57.02. The company’s fifty day moving average price is $50.93 and its 200 day moving average price is $46.59.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. Ralliant’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is presently 10.20%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on RAL shares. Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Friday, February 6th. Morgan Stanley reiterated an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a report on Friday, February 6th. Barclays lowered their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday. Royal Bank Of Canada cut their price target on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 6th. Finally, Truist Financial lowered their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.50.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders have been buying shares, signaling management confidence — Director Kate Mitchell purchased 2,350 shares at ~$42.48 and Director Anelise Angelino Sacks bought 2,000 shares (disclosed in SEC filings). These purchases can support the stock and signal perceived undervaluation. Kate Mitchell SEC Filing Anelise Angelino Sacks SEC Filing
• Neutral Sentiment: Management will present at upcoming investor conferences (Citi and Barclays on Feb 17–18), offering a platform to clarify strategy and guidance — useful for investors seeking more detail but not an immediate catalyst. Conference Announcement
• Neutral Sentiment: Several sell‑side firms trimmed price targets (Barclays, Citigroup, Truist, Oppenheimer) — these lower targets reduce near‑term enthusiasm but many analysts retained positive ratings, leaving mixed guidance for investors. Barclays / Analyst Notes
• Negative Sentiment: Ralliant disclosed a roughly $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 guidance — a material accounting charge and weaker outlook that hit fundamentals and triggered large analyst re‑ratings. Impairment / Guidance Report
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Block & Leviton, Kaplan Fox and others) have opened or publicized investigations into possible securities‑law violations related to the impairment timing/disclosure — raising litigation, regulatory and reputational risk. Kessler Topaz PR Block & Leviton Alert
• Negative Sentiment: Short interest rose sharply (~+58.7% in January to ~3.75M shares), amplifying downside pressure and intraday volatility as bearish positioning increases the risk of further selling on negative headlines.
• Negative Sentiment: Zacks downgraded Ralliant to a “strong sell,” adding to negative analyst momentum and likely contributing to selling pressure. Zacks Note

Institutional Trading of Ralliant

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in shares of Ralliant during the 4th quarter valued at approximately $20,524,000. HRT Financial LP increased its stake in Ralliant by 77.8% during the fourth quarter. HRT Financial LP now owns 165,544 shares of the company’s stock worth $8,427,000 after acquiring an additional 72,439 shares during the last quarter. SMA Capital LLC purchased a new stake in Ralliant in the fourth quarter valued at $4,582,000. Renaissance Technologies LLC lifted its stake in shares of Ralliant by 70.3% in the 4th quarter. Renaissance Technologies LLC now owns 288,502 shares of the company’s stock valued at $14,688,000 after purchasing an additional 119,102 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Ralliant by 10.9% during the 4th quarter. New York State Common Retirement Fund now owns 99,215 shares of the company’s stock worth $5,051,000 after purchasing an additional 9,737 shares during the period.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.